Zealand Pharma A/S
CSE:ZEAL

Watchlist Manager
Zealand Pharma A/S Logo
Zealand Pharma A/S
CSE:ZEAL
Watchlist
Price: 514.2 DKK 0.43%
Market Cap: 36.7B DKK

Wall Street
Price Targets

ZEAL Price Targets Summary
Zealand Pharma A/S

Wall Street analysts forecast ZEAL stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ZEAL is 766.08 DKK with a low forecast of 404 DKK and a high forecast of 1 176 DKK.

Lowest
Price Target
404 DKK
21% Downside
Average
Price Target
766.08 DKK
49% Upside
Highest
Price Target
1 176 DKK
129% Upside
Zealand Pharma A/S Competitors:
Price Targets
214450
PharmaResearch Co Ltd
98% Upside
002675
Yantai Dongcheng Biochemicals Co Ltd
27% Upside
300653
Yantai Zhenghai Bio-Tech Co Ltd
24% Upside
SOBI
Swedish Orphan Biovitrum AB (publ)
9% Upside
300142
Walvax Biotechnology Co Ltd
37% Downside
251120
Bio-FD&C Co Ltd
19% Upside
ASMB
Assembly Biosciences Inc
9% Upside
GILD
Gilead Sciences Inc
9% Upside

Revenue
Forecast

Revenue Estimate
Zealand Pharma A/S

For the last 13 years the compound annual growth rate for Zealand Pharma A/S's revenue is -6%. The projected CAGR for the next 3 years is 283%.

-6%
Past Growth
283%
Estimated Growth
Estimates Accuracy
-12%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Zealand Pharma A/S

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Net Income
Forecast

Net Income Estimate
Zealand Pharma A/S

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-45%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is ZEAL's stock price target?
Price Target
766.08 DKK

According to Wall Street analysts, the average 1-year price target for ZEAL is 766.08 DKK with a low forecast of 404 DKK and a high forecast of 1 176 DKK.

What is Zealand Pharma A/S's Revenue forecast?
Projected CAGR
283%

For the last 13 years the compound annual growth rate for Zealand Pharma A/S's revenue is -6%. The projected CAGR for the next 3 years is 283%.

Back to Top